TRAILBLAZER‐ALZ 4: Directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease ‐ Results from 12‐months

TRAILBLAZER‐ALZ 4: Directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease ‐ Results from 12‐months

Background TRAILBLAZER‐ALZ 4 demonstrated superiority of donanemab versus aducanumab at the 6‐month primary endpoint of the percentage of participants achieving amyloid plaque clearance (

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alzheimer's & dementia 2023-12, Vol.19 (S24), p.n/a
Hauptverfasser: Pain, Andrew, Ferguson, Margaret B, Wang, Hong, Salloway, Stephen, Lee, Elly, Papka, Michelle, Hu, Haoyan B, Lu, Ming, Oru, Ena B, Collins, Emily C., Brooks, Dawn A., Sims, John R.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background TRAILBLAZER‐ALZ 4 demonstrated superiority of donanemab versus aducanumab at the 6‐month primary endpoint of the percentage of participants achieving amyloid plaque clearance (
ISSN:1552-5260
1552-5279
DOI:10.1002/alz.082529